0001213900-24-064557.txt : 20240802 0001213900-24-064557.hdr.sgml : 20240802 20240802131651 ACCESSION NUMBER: 0001213900-24-064557 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240802 DATE AS OF CHANGE: 20240802 EFFECTIVENESS DATE: 20240802 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Silo Pharma, Inc. CENTRAL INDEX KEY: 0001514183 STANDARD INDUSTRIAL CLASSIFICATION: APPAREL & OTHER FINISHED PRODS OF FABRICS & SIMILAR MATERIAL [2300] ORGANIZATION NAME: 04 Manufacturing IRS NUMBER: 462137136 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-520467 FILM NUMBER: 241169840 BUSINESS ADDRESS: STREET 1: 677 N. WASHINGTON BLVD CITY: SARASOTA STATE: FL ZIP: 34236 BUSINESS PHONE: (718) 400-9031 MAIL ADDRESS: STREET 1: 677 N. WASHINGTON BLVD CITY: SARASOTA STATE: FL ZIP: 34236 FORMER COMPANY: FORMER CONFORMED NAME: Uppercut Brands, Inc. DATE OF NAME CHANGE: 20190808 FORMER COMPANY: FORMER CONFORMED NAME: Point Capital, Inc. DATE OF NAME CHANGE: 20130130 FORMER COMPANY: FORMER CONFORMED NAME: Gold Swap Inc DATE OF NAME CHANGE: 20110301 D 1 primary_doc.xml X0708 D LIVE 0001514183 Silo Pharma, Inc. 677 N. WASHINGTON BOULEVARD SARASOTA FL FLORIDA 34236 (718) 400-9031 NEVADA Gold Swap Inc. Uppercut Brands, Inc. Point Capital, Inc. Gold Swap Inc Corporation true Eric Weisblum 677 N. Washington Boulevard Sarasota FL FLORIDA 34236 Executive Officer Director Chief Executive Officer Daniel Ryweck 677 N. Washington Boulevard Sarasota FL FLORIDA 34236 Executive Officer Chief Financial Officer Wayne Linsley 677 N. Washington Boulevard Sarasota FL FLORIDA 34236 Director Kevin Munoz 677 N. Washington Boulevard Sarasota FL FLORIDA 34236 Director Jeff Pavell 677 N. Washington Boulevard Sarasota FL FLORIDA 34236 Director Pharmaceuticals Decline to Disclose 06b false 2024-07-18 false true true true false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 PARK AVENUE NEW YORK NY NEW YORK 10022 FL FLORIDA NY NEW YORK false 2296880 2296880 0 The offering amount reflects the aggregate purchase price received and exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors and placement agent in the private placement under Rule 506(b). false 2 157500 0 In connection with the Registered Direct Offering concurrent with the Private Placement, the Placement Agent received $157,500 in fees and warrants to purchase up to 57,273 shares of common stock exercisable at $3.4375 per share. 0 false Silo Pharma, Inc. /s/ Eric Weisblum Eric Weisblum Chief Executive Officer 2024-08-02